Pfizer has signed a licensing deal with Starna Therapeutics worth $2.6 billion to expand its inflammation and immunology pipeline through in vivo CAR-T programs aimed at autoimmune diseases. Pfizer will pay $330 million upfront and could deliver up to $2.3 billion in development and commercial milestones. Under the agreement, Pfizer gains exclusive rights outside Mainland China, Hong Kong, Macau, and Taiwan to develop, manufacture, and commercialize up to three pre-IND in vivo CAR-T programs. The company will also use Starna’s proprietary targeted lipid nanoparticle RNA delivery and in vivo CAR-T technology, with Pfizer planning to lead clinical development. Starna, which positions its lipid nanoparticle delivery platform as a foundation for scalable immune engineering, will see Pfizer lead execution through its U.S. facilities. The structure also leaves room for Pfizer to optionally license compounds from a separate research collaboration. For the biotech sector, the deal underscores how large pharma is moving to de-risk platform assets for next-generation cell-therapy-like mechanisms that may be delivered as RNA payloads—potentially simplifying manufacturing and patient logistics compared with ex vivo autologous approaches.
Get the Daily Brief